Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content

PC2: Preparation for neonates – a sensitive population

Room:

114

Facilitator:

Sviestiņa, Inese

Speakers:

Abstract:

ACPE UAN: 0475-0000-19-017-L07-P. A knowledge based activity.

Linked to EAHP Statements

Section 3 – Production and Compounding: Statement 3.1
Section 4 – Clinical Pharmacy Services: Statements 4.5, 4.7

Abstract

To minimise the risks in the reconstitution of medication preparations to neonates in clinical areas there is an EU resolution for i) risk handling, ii)handling requirements and iii) responsibilities. When considering the formulation of the medication, availability of suitable administration forms and concentration as well as appropriate osmolarity must be considered. Despite widespread use of different excipients in medicines for neonates, there is a lack of detailed description regarding the extent of such use in neonatal medicines, the pharmacokinetics and safety of many of these agents (e.g., ethanol, benzoates) are still not well described. Although excipients should have limited pharmacological activity, there is an increasing number of adverse reports in a paediatric population. This is mainly because pharmacokinetics and pharmacodynamics of excipients in neonates may have different activity if to be compared with adults and therefore could create adverse reactions.

Learning objectives

After the seminar, participants should be able to:
• describe effects of potentially harmful excipients;
• list examples of potentially harmful excipients;
• describe preparation risks in the ward and risk mitigation strategies.

Educational need addressed

Hospital pharmacists need to be aware of effects of potentially harmful excipients and should be able to educate other healthcare specialists.

Keywords: neonates, potentially harmful excipients, preparation.

×

EAHP Forum

All the EAHP team is working on providing a Forum that can help connect all the members in Conversations and Groups to talk about important matters for the European Hospital Pharmacist.

The Forum will be accessible for all the EAHP members, you don’t have to create a new account to browse and participate.

Conversations and groups

The Conversations will be moderated by our team to provide documents and relevant topics for the community.

The Groups will connect all members that share a category. Members who work on the same assocation, on the same hospital, that have the same role, etc.

Stay tuned for the realase of the forum. Soon on EAHP.